» Articles » PMID: 35938257

Management of Sleep Disturbances in Parkinson's Disease

Overview
Publisher Sage Publications
Specialty Neurology
Date 2022 Aug 8
PMID 35938257
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson's disease (PD) is defined by its motor symptoms rigidity, tremor, and akinesia. However, non-motor symptoms, particularly autonomic disorders and sleep disturbances, occur frequently in PD causing equivalent or even greater discomfort than motor symptoms effectively decreasing quality of life in patients and caregivers. Most common sleep disturbances in PD are insomnia, sleep disordered breathing, excessive daytime sleepiness, REM sleep behavior disorder, and sleep-related movement disorders such as restless legs syndrome. Despite their high prevalence, therapeutic options in the in- and outpatient setting are limited, partly due to lack of scientific evidence. The importance of sleep disturbances in neurodegenerative diseases has been further emphasized by recent evidence indicating a bidirectional relationship between neurodegeneration and sleep. A more profound insight into the underlying pathophysiological mechanisms intertwining sleep and neurodegeneration might lead to unique and individually tailored disease modifying or even neuroprotective therapeutic options in the long run. Therefore, current evidence concerning the management of sleep disturbances in PD will be discussed with the aim of providing a substantiated scaffolding for clinical decisions in long-term PD therapy.

Citing Articles

From Night to Light: A Bibliometric Analysis of the Global Research Trajectory of Sleep Disorders in Parkinson's Disease.

Shi L, Zhao X, Wu J, He C J Multidiscip Healthc. 2025; 18:473-492.

PMID: 39902191 PMC: 11789777. DOI: 10.2147/JMDH.S503849.


Tryptophan metabolism-related gene CYP1B1 serves as a shared biomarker for both Parkinson's disease and insomnia.

Li X, Yu W, Wu J, He W, Cheng Y, Gao K Sci Rep. 2025; 15(1):1362.

PMID: 39779759 PMC: 11711247. DOI: 10.1038/s41598-024-84362-8.


Diagnosis and treatment of autonomic failure, pain and sleep disturbances in Parkinson's disease: guideline "Parkinson's disease" of the German Society of Neurology.

Fanciulli A, Sixel-Doring F, Buhmann C, Krismer F, Hermann W, Winkler C J Neurol. 2025; 272(1):90.

PMID: 39751950 PMC: 11698777. DOI: 10.1007/s00415-024-12730-5.


Effect of zonisamide on sleep and rapid eye movement sleep behavioral disorders in patients with Parkinson's disease: A randomized control trial.

Kataoka H, Isogawa M, Nanaura H, Kurakami H, Hasebe M, Kinugawa K Clin Park Relat Disord. 2024; 11:100285.

PMID: 39650051 PMC: 11625216. DOI: 10.1016/j.prdoa.2024.100285.


Diagnostic and therapeutic challenges in PD-associated non-motor symptoms: the roles of neurologists and consultant physicians.

Ip C, Kassubek J, Storch A, Tonges L, Wolz M, Jost W J Neural Transm (Vienna). 2024; 131(10):1263-1273.

PMID: 39370478 DOI: 10.1007/s00702-024-02838-3.


References
1.
Pagano G, De Micco R, Yousaf T, Wilson H, Chandra A, Politis M . REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. Neurology. 2018; 91(10):e894-e905. DOI: 10.1212/WNL.0000000000006134. View

2.
Redline S, Strauss M, Adams N, Winters M, Roebuck T, Spry K . Neuropsychological function in mild sleep-disordered breathing. Sleep. 1997; 20(2):160-7. DOI: 10.1093/sleep/20.2.160. View

3.
Postuma R, Anang J, Pelletier A, Joseph L, Moscovich M, Grimes D . Caffeine as symptomatic treatment for Parkinson disease (Café-PD): A randomized trial. Neurology. 2017; 89(17):1795-1803. PMC: 5664303. DOI: 10.1212/WNL.0000000000004568. View

4.
Covassin N, Neikrug A, Liu L, Corey-Bloom J, Loredo J, Palmer B . Clinical correlates of periodic limb movements in sleep in Parkinson's disease. J Neurol Sci. 2012; 316(1-2):131-6. PMC: 3321115. DOI: 10.1016/j.jns.2012.01.004. View

5.
Raposo Pereira F, McMaster M, de Vries Y, Polderman N, van den Brink W, van Wingen G . Influence of Gamma-Hydroxybutyric Acid-Use and Gamma-Hydroxybutyric Acid-Induced Coma on Affect and the Affective Network. Eur Addict Res. 2019; 25(4):173-181. PMC: 7050670. DOI: 10.1159/000497381. View